Gilead Sciences (GILD) PT Raised at Cowen as HCV Sales Drive Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences (GILD) raises Revenue Guidance Following 3Q Beat; Maxim Group Reiterates Buy
October 28, 2015 1:47 PM EDTMaxim Group reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target to $137.00 (from $129.00), following the company's 3Q earnings results. Gilead delivered a very strong quarter well ahead of street estimates. Gilead raised guidance for full year... More
Gilead Sciences (GILD) Bullish Stance Reiterated at Oppenheimer Amid 'Beat and Raise' Qtr
October 28, 2015 6:25 AM EDTOppenheimer analyst Wendy Lam reiterated an Outperform rating and $124 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q3.
Lam commented, "GILD reported a healthy 3Q15 beat, with revenue and non-GAAP EPS of $8.30B and $3.22 topping Street consensus estimates of $7.81B and $2.87; GILD... More
Gilead (GILD) Slips Despite Strong Q3 Results
October 27, 2015 4:13 PM EDTGilead (NASDAQ: GILD) reported third quarter financial results today after the market close and the stock is trading down by 1.8% in the aftermarket. Revenue of $8.7 billion beat expectations of $7.8 billion. EPS of $3.22 beat consensus of $2.83.
Breaking down the numbers by therapy, HCV... More
Gilead Sciences (GILD) Tops Q3 EPS by 33c, Updates FY15 Guidance
October 27, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $8.3 billion versus the consensus estimate of $7.82 billion.
Product Sales
Total product sales for the third quarter of 2015 were $8.2 billion compared to $6.0... More
